We design and apply unique patient-based cellular assays for large-scale phenotypic screening, leaning on the power of AI-driven image analysis. Integrated from bed to bench and back to bed, we aim to generate most efficient first-in-class therapeutic molecules for next generation medicine.
Expertise
From patient-based disease models to novel therapeutic molecules.
Pipeline
Innovation holds the key. Our pipeline of drug discovery programs.
Partner with us
Initiate, codevelop or support our discovery programs.
Newsroom
Keep posted about
our latest developments
and achievements
Review Article in JAMA Psychiatry
Schumann G, Andreassen OA, Banaschewski T, et al. Addressing Global Environmental Challenges to Mental Health Using Population Neuroscience: A Review. JAMA Psychiatry....
Press Release of the IMPACT consortium, engaged in finding novel therapies to fight Arrhythmogenic Cardiomyopathy
Thanks to the funding obtained from Horizon Europe, this research project aims to open up new therapeutic perspectives based on the results obtained from various disease models....
New publication in “Nature Communications”
Lamiable, A., Champetier, T., Leonardi, F. et al. Revealing invisible cell phenotypes with conditional generative modeling. Nat Commun 14, 6386 (2023). Biological sciences, drug...
They trust us
“Patient-derived disease models used for phenotypic drug discovery purposes carry a huge potential. We strongly believe in Ksilink as a key player for effectively bridging the gap between scientific excellence and the pharma industry.”
Jacques Volckmann, Head of R&D, Sanofi, France
“Ksilink’s capacities to apply patient-derived disease models for high-throughput, high-content screening by using AI-driven deep learning computation is outstanding.”
Wolfram Zimmermann, CSO, Myriamed GmbH, Germany
“Bridging the gap between academic clinical research and industry is key to enable the precision medicine of tomorrow. We see big value in the ability of Ksilink to translate clinical expertise into treatment for diseases with high unmet medical need .”
Andreas Meyer-Lindenberg, Director and CEO, Central Institute of Mental Health, Germany
“Phenotypic screening using most authentic disease models is clearly paving the way towards next generation medicine. We strongly believe in Ksilink’s potential, allowing the generation of valuable first-in-class therapeutic molecules.”
Bert Klebl, Managing Director of Lead Discovery Center, Germany